Circular Genomics, Altoida Combine Blood and Digital Biomarkers for Alzheimer's
San Diego – September 22, 2026 -- Circular Genomics and Altoida have entered a collaboration pairing blood-based circular RNA (circRNA) biomarkers with AI-powered digital cognitive testing to accelerate Alzheimer's drug development and build a scalable frontline diagnostic pathway.
Companies design a two-step diagnostic workflow combining digital and molecular data
The alliance links Circular Genomics' CircPathTM circRNA biomarker platform with Altoida's Digital NeuroMarkerTM platform. The proposed workflow starts with a 10-minute, self-administered digital cognitive assessment, followed by a confirmatory circRNA blood test to validate underlying disease biology. The companies say this sequence could reduce dependence on hours-long, specialist-administered neuropsychological batteries and extend Alzheimer's screening into primary care settings.